View source for Brexucabtagen-Autoleucel

{{Definitions
|Term=Brexucabtagen-Autoleucel
|Short definition=Brexucabtagen-Autoleucel - {{Pronunciation}} (brek-suh-KAB-tuh-jeen aw-toh-LOO-sel) A drug used to treat adults with mantle cell lymphoma or B-cell acute lymphoblastic leukemia that has come back or has not improved after other treatment. It is also being studied in the treatment of other types of cancer. 
|Type=Cancer terms
|Specialty=Oncology
|Language=English
|Source=NCI
}}
Brexucabtagen-Autoleucel - {{Pronunciation}} (brek-suh-KAB-tuh-jeen aw-toh-LOO-sel) A drug used to treat adults with mantle cell lymphoma or B-cell acute lymphoblastic leukemia that has come back or has not improved after other treatment. It is also being studied in the treatment of other types of cancer. Brexucabtagene-Autoleucel is made using a patient's T cells (a type of cell in the immune system). A gene for a special receptor called the chimeric antigen receptor (CAR) is added to the T cells in the laboratory. Large numbers of these modified T cells, known as CAR T cells, are cultivated in the laboratory and given to the patient by infusion. Brexucabtagene autoleucel attaches to a protein called CD19, which is found on some lymphoma cells and leukemia cells. This helps the body's immune system kill cancer cells. Brexucabtagene Autoleucel is a form of CAR T cell therapy. Also called Tecartus {{dictionary-stub}} [[Category:Dictionary of medicine]]